Bio-Rad Laboratories, Inc. (BIO) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Devices
EV/EBITDA
↓
18.13
↓-25% vs avg
5yr avg: 24.20
30Y Low5.4·High35.4
P/FCF
↓
20.36
↓-66% vs avg
5yr avg: 59.74
30Y Low10.8·High156.0
P/B Ratio
↓
1.03
↓-21% vs avg
5yr avg: 1.31
30Y Low1.1·High3.1
ROE
↓
10.8%
↓+456% vs avg
5yr avg: -3.0%
30Y Low-31%·High49%
Debt/EBITDA
↑
3.22
↑+36% vs avg
5yr avg: 2.37
30Y Low0.2·High14.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BIO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bio-Rad Laboratories, Inc. trades at 10.1x earnings, 25% above its 5-year average of 8.1x, sitting at the 12th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 54%. On a free-cash-flow basis, the stock trades at 20.4x P/FCF, 66% below the 5-year average of 59.7x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.6B | $8.3B | $9.3B | $9.4B | $12.5B | $22.8B | $17.6B | $11.2B | $7.0B | $7.2B | $5.4B |
| Enterprise Value | $8.6B | $9.3B | $10.2B | $10.4B | $13.5B | $22.6B | $17.1B | $11.2B | $7.0B | $7.2B | $5.4B |
| P/E Ratio → | 10.13 | 10.87 | — | — | — | 5.37 | 4.62 | 6.35 | 19.45 | 58.64 | 207.14 |
| P/S Ratio | 2.95 | 3.20 | 3.61 | 3.53 | 4.47 | 7.81 | 6.91 | 4.83 | 3.07 | 3.32 | 2.61 |
| P/B Ratio | 1.03 | 1.11 | 1.41 | 1.08 | 1.30 | 1.67 | 1.78 | 1.94 | 1.75 | 2.45 | 2.10 |
| P/FCF | 20.36 | 22.07 | 34.82 | 43.21 | 155.99 | 42.60 | 36.90 | 31.08 | 45.09 | — | 72.54 |
| P/OCF | 14.33 | 15.53 | 20.36 | 25.15 | 64.41 | 34.09 | 30.06 | 24.39 | 24.59 | 68.83 | 25.01 |
P/E links to full P/E history page with 30-year chart
BIO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Bio-Rad Laboratories, Inc.'s enterprise value stands at 18.1x EBITDA, 25% below its 5-year average of 24.2x. The Healthcare sector median is 14.2x, placing the stock at a 28% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.59 | 3.96 | 3.91 | 4.81 | 7.73 | 6.74 | 4.83 | 3.07 | 3.34 | 2.60 |
| EV / EBITDA | 18.13 | 19.47 | 24.14 | 21.57 | 20.43 | 35.39 | 30.62 | 27.61 | 238.55 | 27.21 | 27.45 |
| EV / EBIT | 31.89 | 34.25 | — | — | — | 4.14 | 3.47 | 4.88 | 13.10 | 59.75 | 82.88 |
| EV / FCF | — | 24.73 | 38.15 | 47.80 | 167.87 | 42.14 | 35.99 | 31.05 | 45.14 | — | 72.25 |
BIO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Bio-Rad Laboratories, Inc. earns an operating margin of 10.5%. Operating margins have compressed from 12.6% to 10.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 10.8% is modest. ROIC of 2.6% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.0% | 52.0% | 53.7% | 53.4% | 55.9% | 56.1% | 56.5% | 54.4% | 53.5% | 55.0% | 55.0% |
| Operating Margin | 10.5% | 10.5% | 10.5% | 12.6% | 17.2% | 17.1% | 16.6% | 9.9% | -4.7% | 5.4% | 2.6% |
| Net Profit Margin | 29.4% | 29.4% | -71.9% | -23.9% | -129.5% | 145.6% | 149.8% | 76.1% | 15.8% | 5.3% | 1.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.8% | 10.8% | -24.1% | -6.9% | -31.1% | 36.1% | 48.8% | 36.0% | 10.4% | 4.2% | 1.1% |
| ROA | 7.6% | 7.6% | -17.0% | -4.9% | -23.2% | 27.7% | 36.4% | 25.8% | 7.3% | 2.8% | 0.7% |
| ROIC | 2.6% | 2.6% | 2.3% | 2.5% | 3.0% | 3.3% | 4.2% | 3.5% | -2.3% | 3.2% | 1.6% |
| ROCE | 2.9% | 2.9% | 2.6% | 2.7% | 3.2% | 3.4% | 4.3% | 3.7% | -2.4% | 3.3% | 1.6% |
BIO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Bio-Rad Laboratories, Inc. carries a Debt/EBITDA ratio of 3.2x, which is moderately leveraged (roughly in line with the sector average of 3.2x). Net debt stands at $999M ($1.5B total debt minus $532M cash). Interest coverage of 5.5x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.21 | 0.21 | 0.16 | 0.14 | 0.02 | 0.02 | 0.11 | 0.11 | 0.15 | 0.17 |
| Debt / EBITDA | 3.22 | 3.22 | 3.27 | 2.91 | 2.10 | 0.35 | 0.40 | 1.61 | 14.92 | 1.64 | 2.22 |
| Net Debt / Equity | — | 0.13 | 0.13 | 0.11 | 0.10 | -0.02 | -0.04 | -0.00 | 0.00 | 0.02 | -0.01 |
| Net Debt / EBITDA | 2.10 | 2.10 | 2.11 | 2.07 | 1.45 | -0.39 | -0.78 | -0.02 | 0.27 | 0.19 | -0.11 |
| Debt / FCF | — | 2.67 | 3.33 | 4.59 | 11.88 | -0.46 | -0.92 | -0.03 | 0.05 | — | -0.29 |
| Interest Coverage | 5.52 | 5.52 | -46.90 | -16.20 | -122.43 | 3514.25 | 225.97 | 97.56 | 22.39 | 5.25 | 2.78 |
BIO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Bio-Rad Laboratories, Inc.'s current ratio of 5.62x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 4.19x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.83x to 5.62x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.62 | 5.62 | 6.48 | 5.83 | 5.55 | 2.92 | 3.39 | 2.41 | 4.49 | 3.93 | 3.91 |
| Quick Ratio | 4.19 | 4.19 | 4.85 | 4.34 | 4.29 | 2.08 | 2.40 | 1.80 | 3.19 | 2.75 | 2.80 |
| Cash Ratio | 2.98 | 2.98 | 3.56 | 3.07 | 3.15 | 1.28 | 1.57 | 1.23 | 1.87 | 1.50 | 1.78 |
| Asset Turnover | — | 0.24 | 0.27 | 0.22 | 0.21 | 0.16 | 0.20 | 0.29 | 0.41 | 0.51 | 0.54 |
| Inventory Turnover | 1.67 | 1.67 | 1.56 | 1.59 | 1.72 | 2.24 | 1.78 | 1.90 | 1.83 | 1.64 | 1.77 |
| Days Sales Outstanding | — | 66.76 | 64.35 | 66.82 | 64.43 | 52.90 | 60.14 | 62.00 | 62.55 | 78.55 | 65.71 |
BIO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bio-Rad Laboratories, Inc. returns 3.9% to shareholders annually primarily through share buybacks. The earnings yield of 9.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 9.9% | 9.2% | — | — | — | 18.6% | 21.6% | 15.7% | 5.1% | 1.7% | 0.5% |
| FCF Yield | 4.9% | 4.5% | 2.9% | 2.3% | 0.6% | 2.3% | 2.7% | 3.2% | 2.2% | — | 1.4% |
| Buyback Yield | 3.9% | 3.6% | 2.2% | 4.5% | 1.7% | 0.2% | 0.6% | 0.3% | 0.7% | 0.0% | 0.0% |
| Total Shareholder Yield | 3.9% | 3.6% | 2.2% | 4.5% | 1.7% | 0.2% | 0.6% | 0.3% | 0.7% | 0.0% | 0.0% |
| Shares Outstanding | — | $27M | $28M | $29M | $30M | $30M | $30M | $30M | $30M | $30M | $30M |
Peer Comparison
Compare BIO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BIOYou | $8B | 10.1 | 18.1 | 20.4 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $125B | 35.2 | 18.4 | 23.8 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 BRKR | $9B | -381.5 | 22.9 | 201.2 | 45.9% | 6.9% | -0.4% | 4.4% | 4.5 |
 RGEN | $7B | 153.5 | 54.7 | 79.3 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
 CRL | $9B | -63.6 | 12.9 | 17.2 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 IDXX | $45B | 43.0 | 31.1 | 42.4 | 61.8% | 31.6% | 66.2% | 42.5% | 0.7 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 QGEN | $8B | 18.1 | 11.8 | 16.8 | 61.8% | 24.9% | 11.6% | 8.6% | 2.3 |
 AZTA | $1B | -19.1 | 18.1 | 28.0 | 45.5% | -1.9% | -3.2% | -0.5% | 2.2 |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BIO — Frequently Asked Questions
Quick answers to the most common questions about buying BIO stock.
What is Bio-Rad Laboratories, Inc.'s P/E ratio?
Bio-Rad Laboratories, Inc.'s current P/E ratio is 10.1x. The historical average is 21.1x. This places it at the 12th percentile of its historical range.
What is Bio-Rad Laboratories, Inc.'s EV/EBITDA?
Bio-Rad Laboratories, Inc.'s current EV/EBITDA is 18.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.2x.
What is Bio-Rad Laboratories, Inc.'s ROE?
Bio-Rad Laboratories, Inc.'s return on equity (ROE) is 10.8%. The historical average is 10.4%.
Is BIO stock overvalued?
Based on historical data, Bio-Rad Laboratories, Inc. is trading at a P/E of 10.1x. This is at the 12th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Bio-Rad Laboratories, Inc.'s profit margins?
Bio-Rad Laboratories, Inc. has 52.0% gross margin and 10.5% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Bio-Rad Laboratories, Inc. have?
Bio-Rad Laboratories, Inc.'s Debt/EBITDA ratio is 3.2x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.